XML 34 R18.htm IDEA: XBRL DOCUMENT v3.21.2
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SCHEDULE OF DISAGGREGATED REVENUE

For the three and six months ended June 30, 2021 and 2020, the Company had the following disaggregated revenue:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   %   2020   %   2021   %   2020   % 
Product revenues by Brand for Conversion Labs PR:                                        
Rex MD  $12,128,524    54%  $1,835,503    20%  $21,969,077    55%  $2,328,276    18%
Shapiro MD   3,515,631    16%   5,881,965    65%   6,899,414    17%   8,219,073    61%
Nava MD   108,252    1%   -    -%   108,252    -%   -    -%
iNR Wellness   19,737    -%   71,162    1%   43,642    -%   141,090    1%
Purpurex   27,466    -%   79,426    1%   62,540    -%   132,948    1%
Scarology   -    -%   1,757    -%   -    -%   4,227    -%
Total product revenue for Conversion Labs PR  $15,799,610    71%  $7,869,813    87%  $29,082,925    72%  $10,825,614    81%
Software revenue for LegalSimpli   6,514,001    29%   1,219,970    13%   11,428,798    28%   2,568,981    19%
Total net revenue  $22,313,611    100%  $9,089,783    100%  $40,511,723    100%  $13,394,595    100%
SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY

The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the in-process monthly or yearly contracts with customers and a portion attributable to the yet to be recognized initial 14-day trial period collections.

 

   2021  2020  2021  2020
   Three Months Ended June 30,  Six Months Ended June 30,
   2021  2020  2021  2020
Beginning of period  $1,339,309   $302,960   $916,880   $109,552 
Additions   6,183,965    1,127,862    11,210,719    2,484,256 
Revenue recognized   6,141,336    1,127,152    10,745,661    2,290,138 
End of period  $1,381,938   $303,670   $1,381,938   $303,670 
SUMMARY OF INVENTORY

As of June 30, 2021 and December 31, 2020, the Company’s inventory consisted of the following:

 

   June 30,   December 31, 
   2021   2020 
         
Finished Goods - Products  $1,526,491    1,172,624 
Raw materials and packaging components   87,626    149,115 
Inventory reserve   -    (57,481)
Total Inventory - net  $1,614,117   $1,264,258 
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price could be less than the average market price of the common shares:

 

  

Three Months

Ended

  

Three Months

Ended

  

Six Months

Ended

  

Six Months

Ended

 
  

June 30, 2021

  

June 30, 2020

  

June 30, 2021

  

June 30, 2020

 
                 
Series B Preferred Stock   1,076,923    -    1,076,923    - 
Restricted Stock Units (RSUs)   664,375    -    355,938    - 
Stock options   4,013,400    4,469,000    4,204,200    4,169,000 
Warrants   3,984,787    1,407,636    3,767,629    2,167,136 
Potentially dilutive securities   9,739,485    5,876,636    9,404,690    6,336,136